Successful treatment of severe abulia with co-beneldopa.
Abulia is a disorder of the executive and frontal lobe function. It is characterised by severe psychomotor slowing that is not due to depressive illness or catatonic schizophrenia. Abulia is thought to be due to disruption of the meso-cortico-limbic dopaminergic system. Preliminary evidence suggests that patients with abulia may respond to treatment with dopaminergic drugs. We extend this evidence by reporting a significant and sustained functional improvement in a severely abulic patient after treatment with co-beneldopa (Madopar).
Moseley Hall Hospital, Birmingham, UK. Magid.bakheit@bhamcommunity.nhs.uk
A M O
AM
Bakheit
K
K
Fletcher
A
A
Brennan
D001545:Benserazide / Q000627:therapeutic use*; D003388:Cranial Fossa, Posterior; D015259:Dopamine Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006849:Hydrocephalus / Q000150:complications; D007980:Levodopa / Q000627:therapeutic use*; D008577:Meningeal Neoplasms / Q000150:complications; D008579:Meningioma / Q000150:complications; D008875:Middle Aged; D011596:Psychomotor Disorders / Q000188:drug therapy* / Q000209:etiology; D013064:Speech Disorders / Q000188:drug therapy / Q000209:etiology
D015259:Dopamine Agents; D004338:Drug Combinations; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D001545:Benserazide